Company profile 2018-04-11T12:49:04+00:00

DelSiTech
in a nutshell

DelSiTech is an innovative drug delivery and development company that works with its partners to turn their active agents into novel and commercially attractive therapeutic drug products.

DelSiTech provides the technology and expertise for solving drug delivery problems. The company’s technology is based on amorphous silica (SiO2) matrix and sol-gel encapsulation technique which have significant competitive advantages over other technologies.

In addition, the Company is developing its own pipeline of supergeneric/505(b)(2) products to address significant unmet medical and commercial needs. The lead product, a long acting antiviral product for hepatitis B, will enter the clinic in 2018.

Our values

Our partners come first. We appoint our top teams to all projects and we are committed to exceed expectations. Our virtues, trust and collaboration ensure close co-operation with biotech and pharma partners and the opportunity to adapt to all their needs.

We encourage an entrepreneurial culture that ensures that our teams are agile, innovative and produce high-quality solutions. We are guided by a long-term vision to provide the best solutions to our partners. Our stable business environment enables us to make long-term investments in all of our working relationships; we can be a continuous partner throughout the development of a product.

COMPANY STRATEGY

DelSiTech aims to become a significant player in the area of controlled release supergeneric/505(b)(2) product development. The Company has a growing pipeline of first-in-class and differentiated products with improved patient compliance. In addition, DelSiTech aims to become the partner of choice for biotech and pharma companies seeking for the best solution for their drug delivery needs.

The Company strategy is to 1) Partner and license its biodegradable silica based drug delivery technology to biotech and pharma industry companies, 2) Develop and commercialize the first in-house controlled release drug product for hepatitis B, and 3) Explore and identify other business opportunities for the silica technology with significant market potential to provide a continuous flow of novel products in the future.

Board

Örjan H. Andersson, D. Sc (Tech)
Örjan H. Andersson, D. Sc (Tech)Chairman of the Board
Dr. Andersson has extensive experience within the biomaterials field, with about 50 scientific publications. He is former Director of Turku Biomaterials centre. He has extensive management experience, including change management and management systems, and is member of the board of several companies. He is current the President of Novia University of Applied Sciences, Finland.
Sebastian Björkstén
Sebastian BjörksténMSc, Member of the Board.
Mr. Björkstén is the Managing Director of several Finnish companies in the consumer business segment.
Jouni Heikkilä, MD, PhD
Jouni Heikkilä, MD, PhDMember of the Board.
Dr. Heikkilä has more than 25 years of experience of clinical practice and researchrelated to biomaterials and orthpedics. He is the Co-Founder and the Member of the Board of several companies. He is Specialistin orthopaedics and traumatology and Director of Traumatri Oy.
 Reijo Salonen, MD, PhD
Reijo Salonen, MD, PhDMember of the Board
Prof. Salonen, specialist in neurology, is the former Vice President, Head of R&D and Chief Medical Officer of Orion Pharma. He has more than 25 years experinece in drug development, especially in clinical development and medical affairs in international pharma industry.
Harry Jalonen, PhD, MBA
Harry Jalonen, PhD, MBAMember of the Board
Dr. Jalonen is the founder and former CEO of DelSiTech Ltd. He has more than 30 years of experience from the pharmaceutical and biotechnology industries. He is the co-founder and the Member of the Board of several biotechnology companies.

Management Team

DelSiTech has at its disposal a world-class organization that has successfully taken pharmaceutical and biomaterial products to the market.

Lasse LeinoPhD, Chief Executive Officer
Dr. Leino is the company’s President and Chief Executive Officer and has more than 20 years life science business experience. He is the founder and former President and CEO of BioCis Pharma Ltd as well as the first CEO and COO of Laurantis Pharma Ltd. Previously, Dr. Leino has worked in various R&D management positions in Orion Pharma, BioTie Therapies Ltd, and AstraZeneca in Lund, Sweden. Dr. Leino holds a PhD in biochemistry and has a position as Adjunct Professor in immunology at the University of Turku, Finland.
Mika JokinenDSc, Research Director
Dr. Jokinen is a co-founder of DelSiTech and Research Director of in the company since 2006. In addition, he is a Principal Lecturer in chemical and biochemical engineering at the Turku University of Applied Sciences. He has over 20 years R&D experience in silica-based biomaterials. Dr. Jokinen holds a Doctor of Science in Technology and has a position as Adjunct Professor in Medical Biomaterials at Åbo Akademi University, Turku, Finland.
Eeva KariMD, Medical Director
Dr. Kari serves as Medical Director in DelSiTech. She has more than 20 years experience in clinical development and medical consulting in pharma and biotech industry. Previously, she worked as Medical Director in Laurantis Pharma. Dr. Kari is specialist in pulmonary diseases.
Cora GriffinPhD, Business Development Director
Dr. Cora Griffin is Director, Head of Business Development of DelSiTech. She joined the company in 2014. Dr. Griffin is a business development and licensing professional with more than 10 years experience in pharma and biotech industry. Previously, she worked at Q Chip Ltd, a polymer-based drug delivery company and Arrow Therapeutics, an antiviral drug development company owned by AstraZeneca. Dr. Griffin holds a PhD in virology.